NASDAQ
17.07.26 | 19:08
0,780 US-Dollar
+8,18 % +0,059
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.06. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tela Bio verfehlt Q1-Prognosen: Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 12.05. | TELA Bio Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 12.05. | TELA Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $19.1M beats by $0.1M | 1 | Seeking Alpha | ||
| 12.05. | TELA Bio, Inc.: TELA Bio Reports First Quarter 2026 Financial Results | 172 | GlobeNewswire (Europe) | MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 12.05. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | TELA Bio, Inc.: TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | 237 | GlobeNewswire (Europe) | MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 21.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 27.03. | Citizens cuts Tela Bio stock price target on commercial transition | 2 | Investing.com | ||
| 25.03. | TELA Bio Analysts Cut Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 25.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.03. | TELA Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Piper Sandler cuts TELA Bio stock price target on lowered outlook | 1 | Investing.com | ||
| 25.03. | Piper Sandler senkt Kursziel für TELA Bio nach schwächerem Ausblick | 1 | Investing.com Deutsch | ||
| 25.03. | Jefferies senkt Kursziel für TELA Bio wegen schwächerer Wachstumsaussichten | 2 | Investing.com Deutsch | ||
| 25.03. | Jefferies cuts TELA Bio stock price target on slower growth outlook | 2 | Investing.com | ||
| 25.03. | Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation | 1 | Seeking Alpha | ||
| 24.03. | TELA Bio: Gewinn übertrifft Erwartungen, doch Umsatz enttäuscht - Aktie bricht ein | - | Investing.com Deutsch | ||
| 24.03. | TELA Bio GAAP EPS of -$0.17 beats by $0.01, revenue of $20.9M misses by $0.14M | 2 | Seeking Alpha |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 54,08 | -2,03 % | Moderna-Aktie mit -11% - Einstieg nach der Korrektur? | Die Moderna-Aktie hat nach ihrer beeindruckenden Rallye zuletzt einen Dämpfer hinnehmen müssen und am gestrigen Handelstag rund -11% an Wert verloren. Damit rückt die Aktie nach dem starken Kursanstieg... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,000 | -0,40 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| MYRIAD GENETICS | 5,336 | -1,08 % | Myriad Genetics, Inc.: New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer | SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,040 | +4,01 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision | King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,410 | +0,16 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| ERASCA | 18,930 | -0,47 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,410 | +11,74 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,03 | -0,04 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | +1,99 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| BEAM THERAPEUTICS | 27,860 | -1,83 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 114,40 | +0,33 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,960 | +2,69 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,820 | +4,27 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +8,18 % bei einem Aktienkurs von 0,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.